IL269895B2 - Coversin for the treatment of autoimmune blistering diseases - Google Patents

Coversin for the treatment of autoimmune blistering diseases

Info

Publication number
IL269895B2
IL269895B2 IL269895A IL26989519A IL269895B2 IL 269895 B2 IL269895 B2 IL 269895B2 IL 269895 A IL269895 A IL 269895A IL 26989519 A IL26989519 A IL 26989519A IL 269895 B2 IL269895 B2 IL 269895B2
Authority
IL
Israel
Prior art keywords
agent
seq
coversin
sequence
protein
Prior art date
Application number
IL269895A
Other languages
English (en)
Hebrew (he)
Other versions
IL269895A (enExample
IL269895B1 (en
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706404.9A external-priority patent/GB201706404D0/en
Priority claimed from GBGB1706452.8A external-priority patent/GB201706452D0/en
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of IL269895A publication Critical patent/IL269895A/en
Publication of IL269895B1 publication Critical patent/IL269895B1/en
Publication of IL269895B2 publication Critical patent/IL269895B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transplantation (AREA)
IL269895A 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases IL269895B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706404.9A GB201706404D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706452.8A GB201706452D0 (en) 2017-04-24 2017-04-24 Method of treatment
PCT/EP2018/060241 WO2018193122A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Publications (3)

Publication Number Publication Date
IL269895A IL269895A (enExample) 2019-12-31
IL269895B1 IL269895B1 (en) 2024-02-01
IL269895B2 true IL269895B2 (en) 2024-06-01

Family

ID=62235916

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269895A IL269895B2 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Country Status (12)

Country Link
US (2) US11730792B2 (enExample)
EP (2) EP4275696A1 (enExample)
JP (2) JP7209637B2 (enExample)
KR (1) KR102656199B1 (enExample)
CN (1) CN110896606B (enExample)
AU (1) AU2018253962B2 (enExample)
CA (1) CA3059657A1 (enExample)
DK (1) DK3612208T5 (enExample)
ES (1) ES2945433T3 (enExample)
IL (1) IL269895B2 (enExample)
PL (1) PL3612208T3 (enExample)
WO (1) WO2018193122A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100396A1 (en) * 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007095230A2 (en) 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US8563521B2 (en) * 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
EP2331564A4 (en) * 2008-10-06 2013-02-20 Carolus Therapeutics Inc PROCESS FOR TREATMENT OF IGNITION
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
CA2785612C (en) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
SMT202100688T1 (it) * 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
WO2016200627A1 (en) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP3307316A1 (en) * 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3328885A1 (en) * 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100396A1 (en) * 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, AKARI THERAPEUTICS - APRIL 2017, 7 April 2017 (2017-04-07) *
ANONYMOUS,, AKARI THERAPEUTICS, 9 January 2017 (2017-01-09) *
S. MIHAI ET AL:, SPECIFIC INHIBITION OF COMPLEMENT ACTIVATION SIGNIFICANTLY AMELIORATES AUTOIMMUNE BLISTERING DISEASE IN MICE, 1 August 2011 (2011-08-01) *
TANYA SEZIN ET AL:, THE LEUKOTRIENE B 4 AND ITS RECEPTOR BLT1 ACT AS CRITICAL DRIVERS OF NEUTROPHIL RECRUITMENT IN MURINE BULLOUS PEMPHIGOID-LIKE EPIDERMOLYSIS BULLOSA ACQUISITA, 17 January 2017 (2017-01-17) *

Also Published As

Publication number Publication date
PL3612208T3 (pl) 2023-07-24
JP7600278B2 (ja) 2024-12-16
JP2023040169A (ja) 2023-03-22
EP3612208B1 (en) 2023-04-05
JP7209637B2 (ja) 2023-01-20
EP4275696A1 (en) 2023-11-15
CN110896606B (zh) 2024-07-16
CA3059657A1 (en) 2018-10-25
EP3612208A1 (en) 2020-02-26
AU2018253962A1 (en) 2019-10-31
DK3612208T3 (da) 2023-05-08
KR20190139233A (ko) 2019-12-17
KR102656199B1 (ko) 2024-04-09
ES2945433T3 (es) 2023-07-03
US20200113971A1 (en) 2020-04-16
WO2018193122A1 (en) 2018-10-25
IL269895A (enExample) 2019-12-31
JP2020517627A (ja) 2020-06-18
US11730792B2 (en) 2023-08-22
US20240009270A1 (en) 2024-01-11
DK3612208T5 (da) 2024-09-02
CN110896606A (zh) 2020-03-20
IL269895B1 (en) 2024-02-01
AU2018253962B2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
TWI784988B (zh) 治療發炎症狀的方法
AU2015270396B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
IL293398B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
JP7629394B2 (ja) リウマチ性疾患の治療に使用するためのコバーシン
JP7603612B2 (ja) 治療法
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism